PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.

Pfizer’s CEO Albert Bourla disclosed that the company recently met with the Trump administration to discuss lowering U.S.

Four blue-chip stocks are trading near their 52-week lows and offering investors incredible entry points and huge dividends.

PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.

Children’s mental health has recently dominated U.S. headlines. Some commentators have blamed psychiatric medications, ...